Clopidogrel improves outcome in an acute coronary syndrome

In the CURE trial, 12,562 patients with an acute coronary syndrome were randomly assigned to clopidogrel or placebo in combination with aspirin. After a one-year follow-up, the incidence of the first primary outcome (cardiovascular death, nonfatal myocardial infarction, or stroke) was significantly lower with clopidogrel (9.3 versus 11.4 percent for placebo). This benefit was largely due to fewer nonfatal infarctions.